Key Findings:  Medical marijuana has emerged as an attractive therapeutic option for CKD, but continues to be used for a variety of unsubstantiated indications with minimal guidance on known risks, particularly with respect to the altered physiological state of patients with CKD. At this time, the supportive evidence for using nonsynthetic cannabinoids for symptom management is limited to the treatment of chronic neuropathic pain, with promising potential when used topically for the treatment of uremic pruritus.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  Canada
Year of Pub:  2019
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Pharma THC:CBD
Phytocannabinoid Source:  Not Applicable